已收盘 02-06 16:00:00 美东时间
+2.000
+3.34%
今日重点评级关注:Benchmark:维持TNL Mediagene"投机性买入"评级,目标价从3.5美元升至14美元;康托·菲茨杰拉德:维持Eupraxia Pharmaceuticals"超配"评级,目标价从11美元升至19美元
01-16 10:04
Barclays analyst Matthew Bouley maintains Fortune Brands (NYSE:FBIN) with a Overweight and raises the price target from $63 to $68.
01-16 01:47
Fortune Brands Innovations, Inc. (NYSE:FBIN), an industry-leading home, security and digital products company whose purpose is to elevate every life by transforming spaces into havens, today announced that its Board of
2025-12-12 05:13
今日重点评级关注:Ascendiant Capital:维持GRI Bio"买入"评级,目标价从35美元升至36美元;Ascendiant Capital:维持Atossa Therapeutics"买入"评级,目标价从7.75美元升至8美元
2025-12-09 10:32
Barclays analyst Matthew Bouley maintains Fortune Brands (NYSE:FBIN) with a Overweight and lowers the price target from $65 to $63.
2025-12-08 23:39
Goldman Sachs sees a familiar pattern returning in 2026: prior-year laggards often beat the S&P 500 in Q1; 2025's underperformers look unusually extreme.
2025-12-05 22:54
今日重点评级关注:康托·菲茨杰拉德:维持Cabaletta Bio"超配"评级,目标价从15美元升至30美元;HC Wainwright & Co.:维持Invivyd"买入"评级,目标价从5美元升至10美元
2025-11-03 20:20
Evercore ISI Group analyst Stephen Kim maintains Fortune Brands (NYSE:FBIN) with a In-Line and lowers the price target from $63 to $55.
2025-10-31 21:11
Fortune Brands Innovations (NYSE:FBIN) declared $0.25/share quarterly dividend, in line with previous. Forward yield 1.88% Payable Dec. 10; for shareholders of record Nov. 21; ex-div Nov. 21. See FBIN...
2025-09-30 04:06